(Nasdaq: ISPH) has launched a Phase I clinical trial of a potential new drug to combat glaucoma.

Some 60 people suffering early-stage glaucoma will participate in the trial.

“This is an important milestone for Inspire as it strengthens our ophthalmic pipeline in disease states with unmet medical need, such as glaucoma, which is the second-leading cause of blindness in the United States,” said R. Kim Brazzell, senior vice president for ophthalmic research and development.